The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Abstract
Background Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. Patients and methods Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Participants were randomly allocated (1 : 1) to receive oral icotinib or 3-week cycle of cisplatin plus pemetrexed for up to four cycles; non-progressive patients after four cycles were maintained with pemetrexed until disease progression or intolerable toxicity. The primary end point was progression-free survival (PFS) assessed by independent response evaluation committee. Other end points included overall survival (OS) and safety. Results Between January 2013 and August 2014, 296 patients were randomized, and 285 patients were treated (148 to icotinib, 137 to chemotherapy). Independent response evaluation committee-assessed PFS was significantly longer in the icotinib group (11.2 versus 7.9 months; hazard ratio, 0.61, 95% confidence interval 0.43-0.87; P = 0.006). No significant difference for OS was observed between treatments in the overall population or in EGFR-mutated subgroups (exon 19 Del/21 L858R). The most…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [149]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610
Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds214 · Cited by 540
Flagged first, then by citations
Research works printed but not linked: 12
- Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 · DOI · Paper page
- Bover, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5 · DOI · Paper page
- Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advancedEGFR, mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X · DOI · Paper page
- Hu, 2012, Synthesis and biological evaluation of crown ether fused quinazoline analogues as potentEGFR inhibitors, Bioorg Med Chem Lett, 22, 6301, 10.1016/j.bmcl.2012.06.067 · DOI
- Shi, 2013, Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial, Lancet Oncol, 14, 953, 10.1016/S1470-2045(13)70355-3 · DOI
- Hu, 2014, A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC), Lung Cancer, 86, 207, 10.1016/j.lungcan.2014.08.014 · DOI
- Shi, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), J Thorac Onco, 9, 154, 10.1097/JTO.0000000000000033 · DOI
- Zhou, 2015, Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment ofEGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802), Ann Oncol, 26, 1877, 10.1093/annonc/mdv276 · DOI · Paper page
- Hu, 2015, The efficacy and safety of icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a single-arm, multi-center, prospective study, PLoS One, 10, e0142500, 10.1371/journal.pone.0142500 · DOI
- Zhang, 2016, Trial-based cost-utility analysis of icotinib versus gefitinib as second-line therapy for advanced non-small cell lung cancer in China, PLoS One, 11, e0151846, 10.1371/journal.pone.0151846 · DOI
- Qian, 2013, Pharmacoeconomic evaluation of EGFR-TKIs in the treatment of advanced non-small cell lung cancer, Chin J Drug Eval, 30, 305
- Liang, 2014, Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboringEGFR mutations, PLoS One, 9, e85245, 10.1371/journal.pone.0085245 · DOI
Cited by
Sorted by citations
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Self-citationShi, Y., Wu, L., Ji, Y., Chen, G., Li, B., Bi, M., Yang, R., Miao, L., Zhang, G., Gao, H., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00121-3 · Cited by 16
Self-citationShi, Y., Bi, M., Li, Q., Wang, G., Chen, J., Li, M., Shi, J., Mei, J., Ji, Y., Xia, Q., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.01.001 · Cited by 2
Self-citation
Metadata
- Authors
- Shi, Y. K., Wang, L., Han, B. H., Li, W., Yu, P., Liu, Y. P., Ding, C. M., Song, X., Ma, Z. Y., Ren, X. L., Feng, J. F., Zhang, H. L., Chen, G. Y., Han, X. H., Wu, N., Yao, C., Song, Y., Zhang, S. C., Song, W., Liu, X. Q., Zhao, S. J., Lin, Y. C., Ye, X. Q., Li, K., Shu, Y. Q., Ding, L. M., Tan, F. L., & Sun, Y.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 28
- Issue
- 10
- Pages
- 2443-2450
- ISSN
- 0923-7534
- Cited by
- 287
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
